Thymosin Alpha-1 Levels and Daily Rhythms Are Disrupted in Women With Inflammatory Gynecologic Diseases

Women with inflammatory gynecologic diseases showed altered thymosin alpha-1 plasma levels and disrupted circadian patterns compared to healthy women, with changes reflecting inflammation type and treatment response.

Shurlygina, A et al.·Bulletin of experimental biology and medicine·2000·Preliminary Evidencecohort
RPEP-00619CohortPreliminary Evidence2000RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
cohort
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Thymosin alpha-1 plasma levels and circadian rhythms were altered in gynecologic inflammation, varying by inflammation type and normalizing with successful treatment.

Key Numbers

How They Did This

Cohort study measuring plasma thymosin alpha-1 concentrations at multiple timepoints in women with inflammatory gynecologic diseases compared to healthy controls.

Why This Research Matters

Thymosin alpha-1 as a treatment response biomarker could help clinicians monitor whether gynecologic inflammation therapy is working without invasive procedures.

The Bigger Picture

Immune peptide rhythms are part of normal health. Their disruption in disease and restoration with treatment provides a non-invasive window into immune system status.

What This Study Doesn't Tell Us

Small study with limited abstract details. Specific inflammation types and sample sizes not described. Circadian sampling adds complexity.

Questions This Raises

  • ?Can thymosin alpha-1 circadian patterns guide treatment timing?
  • ?Do other immune peptides show similar circadian disruption in inflammation?
  • ?Could thymosin alpha-1 supplementation restore disrupted immune rhythms?

Trust & Context

Key Stat:
Rhythms disrupted Not just thymosin alpha-1 levels but their normal day-night cycling was altered in gynecologic inflammation, reflecting disease state
Evidence Grade:
Preliminary clinical evidence with circadian measurements in a relevant patient population, but limited by abstract brevity.
Study Age:
Published in 2000. Thymosin alpha-1's role as an immune biomarker has been supported by subsequent research.
Original Title:
Changes in thymosin-alpha(1)content in patients with nonspecific gynecologic diseases depending on inflammation type and efficacy of antiinflammatory and immunomodulating therapy.
Published In:
Bulletin of experimental biology and medicine, 130(9), 895-7 (2000)
Database ID:
RPEP-00619

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does thymosin alpha-1 tell doctors about inflammation?

When its normal daily rhythm is disrupted and levels are abnormal, it indicates the immune system is fighting inflammation. When levels normalize with treatment, it suggests the therapy is working.

Could this replace invasive tests?

Potentially. A blood test tracking thymosin alpha-1 rhythms could monitor treatment response non-invasively, reducing the need for biopsies or imaging in some gynecologic inflammatory conditions.

Read More on RethinkPeptides

Cite This Study

RPEP-00619·https://rethinkpeptides.com/research/RPEP-00619

APA

Shurlygina, A; Litvinenko, G; Dergacheva, T; Trufakin, V. (2000). Changes in thymosin-alpha(1)content in patients with nonspecific gynecologic diseases depending on inflammation type and efficacy of antiinflammatory and immunomodulating therapy.. Bulletin of experimental biology and medicine, 130(9), 895-7.

MLA

Shurlygina, A, et al. "Changes in thymosin-alpha(1)content in patients with nonspecific gynecologic diseases depending on inflammation type and efficacy of antiinflammatory and immunomodulating therapy.." Bulletin of experimental biology and medicine, 2000.

RethinkPeptides

RethinkPeptides Research Database. "Changes in thymosin-alpha(1)content in patients with nonspec..." RPEP-00619. Retrieved from https://rethinkpeptides.com/research/shurlygina-2000-changes-in-thymosinalpha1content-in

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.